Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (January 2025)
27 slides from Cocrystal Pharma's investor presentation, Jan 13, 2025
Slide 1: Investor Presentation January 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1985, including our development pipeline; our technology platform's ability to produce viable drug candidates at reduced development timelines and co
Slide 3: About Cocrystal Pharma
ut Cocrystal Pharma Advancing programs in high-value antiviral drug targets ° Influenza * Norovirus * Coronavirus and respiratory viruses Applying powerful, proprietary Drug candidates with clinically validated mechanisms of action drug discovery platform + Effectively cure viral diseases technology
Slide 4: Investment Highlights
Investment Highlights ° Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases » Proprietary structure-based drug discovery platform technology provides opportunity for discovery and development of novel, broad-spectrum drug candidates e Advancing multip
Slide 5: Robust Pipeline Addressing Unmet Medical Needs
Robust Pipeline Addressing Unmet Medical Needs Multiple clinical assets poised to deliver significant growth Oral PB2 inhibitor cc-42344 en ocaz34a Replication inhibitors ‘Oral Pan-viral protease inhibitor cDI-988 Norovirus & Coronavirus Norovirus Replication inhibitors Respiratory viruses [MECN aIr
Slide 6: Proprietary Drug Discovery Platform Technology for Direct-Acting Antivirals
Proprietary ig Discovery Platform Technology for Direct-Acting Antivirals Cocrystal’s technology platform provides potential for novel drug candidates at reduced development timelines and costs Grow drug target Select drug Hit-to-lead Lead . . oe Xray crystals —_ binding pocket process optimization
Slide 7: Urgent Unmet Need for Safe, Effective, Broad-Spectrum, Pan-Viral Therapies
Urgent Unmet Need for Safe, Effective, Broad-Spectrum, Pan-Viral Therapies ° Urgent health risks with newly emerging pandemic viral outbreaks‘? * Significant delay of effective new antiviral therapeutics and vaccine development * Challenging issues with current drug discovery approach — one-target/o
Slide 8: Pandemic and Seasonal Influenza Program
Pandemic and Seasonal Influenza Program
Slide 9: Pandemic and Seasonal Influenza: A Major Global Health Concern
Pandemic and Seasonal Influenza: A Major Global Health Concern * 1 billion cases, 3-5 million severe illnesses and up to 650,000 deaths worldwide annually’ * Not well managed with currently approved vaccines having only 40-60% effectiveness? * On average ~8% of the U.S. population contracts influenz
Slide 10: Influenza Development Programs Focused on Therapeutic Inhibitors
Influenza Development Programs Focused on Therapeutic Inhibitors Clinical assets for pandemic and seasonal influenza Promising Early-Stage Programs Oral PB2 in cc * Ongoing Phase 2a study + Discovery ongoing * Potent broad-spectrum activity o Pattent/preatemectmamnamtiaty + Inhibits activity in the
Slide 11: CC-42344 Shows Broad-Spectrum Antiviral Activity Against Influenza A Strains
CC-42344 Shows Broad-Spectrum Antiviral Activity Against Pandemic and Seasonal Influenza A Strains Influenza serotype Strain CC-42344, EC,,n H1N1 AIPR/8/34 1 Pandemic H1N1 California/04/2009 0.5 H1N1 A1/Denver/1/57 3 H1N1 A/Fort Monmouth/1/47 2 H1N1 AINY/18/09 5 H3N2 AJAICHI/2/68 0.2 Highly pathogen
Slide 12: CC-42344 Binds to Highly Conserved Active Site of Influenza A PB2 Protein
CC-42344 Binds to Highly Conserved Active Site of Influenza A PB2 Protein, Cocrystal proprietary drug discovery platform technology > Highly pathogenic influenza A strains H5N1 = eg } H7N9 Qe D Ye £ fee $337 12 C@CRYSTAL a ——
Slide 13: CC-42344 Binds to 2024 Texas Avian Influenza H5N1 PB2 Active Site
CC-42344 Binds to 2024 Texas Avian Influenza H5N1 PB2 Active Site Avian influenza A (H5N1) infection First cocrystal structure of 2024 in dairy cows and human cases H5N1:CC-42344 2024 HPAI:CC-42344 crystals Cocrystal influenza antiviral CC-42344 https:/hnww.cde, gov/bird:-fiu/situation-summary/mamma
Slide 14: CC-42344 Activity in Infected Human Lung Epithelium
‘Gells-are-killed. by WIN 1 virus;and. Uninfected human bronchial = Jmnost cilia-are destroyed= « airway epithelia Influenza A gm H1N1 infection Favorable safety profile: No toxicity in CC-42344- treated human lung epithelium Showed potent antiviral activity in influenza A (H1N1)-infected human lung
Slide 15: CC-42344: Potential Influenza Therapeutic Treatment
CC-42344: Potential Influenza Therapeutic Treatment ° Favorable safety profile and tolerability * Potent, broad-spectrum activity against pandemic and seasonal strains * High barrier to resistance * Oral CC-42344: Human challenge Phase 2a study ongoing in UK * Oral CC-42344: FDA feedback provides im
Slide 16: Norovirus and Coronavirus Program Overview
Norovirus and Coronavirus Program Overview
Slide 17: Norovirus Infection: No Approved Treatments or Vaccines Available
Norovirus Infection: No Approved Treatments or Vaccines Available sie $608 -" ee Norovirus 7 Norovirus Gil. Leading causative age agent of acute viral ‘outbreaks f gastroenteritis CDC: Norovirus Disease in the United States hit fen hia
Slide 18: Significant Unmet Need for New Antivirals to Combat Norovirus Infections
Significant Unmet Need for New Antivirals to Combat Norovirus Infections * Highly contagious virus that causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea * Transmissible by infected person, contaminated food or water, or touching contaminated surfaces * M
Slide 19: Cocrystal Viral Protease Inhibitors Block the Essential Replication Process
Cocrystal Viral Protease Inhibitors Block the Essential Replication Process Norovirus or SARS-CoV-2 Infected cell Membrane fusion Assembly Endocytosis Gilg Uncoating Non-structural Structural RNA Polyproteins Translation Proteolysis Replication Translation Main (3CL) protease inhibitor 19 C@CRYSTAL
Slide 20: First-in-Class Pan-Viral Protease Inhibitor CDI-988
First-in-Class Pan-Viral Protease Inhibitor CDI-988 for Treatment of Norovirus and COVID infections CDI-988, pan-viral protease inhibitor * Developed using Cocrystal’s proprietary drug discovery platform technology ‘ ° Binds to a highly conserved region required for viral proteases CDI-988, pan-vira
Slide 21: Accelerating Progress with First-in-Class Oral Pan-Viral Protease Inhibitor
Accelerating Progress with First-in-Class Oral Pan-Viral Protease Inhibitor CDI-988: Phase 1 Near Completion Phase 1 study in healthy participants to evaluate the safety, tolerability and PK of CDI-988 © Single-center, randomized, double-blind, placebo-controlled * Single-ascending dose and multiple
Slide 22: Experienced Board of Directors
Experienced Board of Directors Roger Kornberg, Ph.D. Co-founder, Chairman of the Board & Nobel Laureate in Chemistry - the process by which genetic information from DNA is copied to RNA ‘Welch Prize — highest award granted in the field of chemistry in the U.S. Chairman of the Scientific + Leopald Ma
Slide 23: Seasoned Leadership
Seasoned Leadership Sam Lee, Ph.D. + Professor Co-Chief Executive Officer & Roger Kornberg, Ph.D. President Chairman of the Board, Chairman of the __ Stanford University School of Medicine i Scientific Advisory Board + Nobel Laureate 25+ years of anti-infective drug icos ny discovery research experi
Slide 24: Expanding Intellectual Property Portfolio
Expanding Intellectual Property Portfolio Coronavirus Norovirus * Issued patents in U.S. and major countries * Issued patents in U.S. and major countries * Pending U.S. provisional applications * Pending U.S. provisional applications Pandemic Influenza A HCV * PB2 (influenza A inhibitor) NSS5B (NNI)
Slide 25: Clinical Milestones
5 Clinical Milestones * CDI-988 as oral treatment and prophylaxis for noroviruses, coronaviruses and other viral infections v Interim topline Phase 1 study results * Phase 1 results including higher-dose cohort * FDA pre-IND meeting * FDAIND submission * Enrollment initiation in norovirus challenge
Slide 26: Financial Snapshot
Financial Snapshot ~$25 Million 42,000 Average 3 month Market cap daily share volume* $13.0 (nulls 0.2M 10.3 Million Cash/equivalents Fully diluted shares Clean balance sheet No preferred shares No debt Cash sufficient to fund planned operations ‘Yahoo Finance (January 6, 2025) 26
Slide 27: Investment Highlights
Investment Highlights oa Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases Proprietary structure-based drug discovery platform technology provides opportunity for discovery and development of novel, broad-spectrum drug candidates Advancing multiple
Cocrystal Pharma — Investor Presentation (January 2025) on 6ix